 |
Attention Deficit Hyperactivity Disorder and Co-Morbid Conditions in Adolescents and Adults CME Co-chairs: Lenard Adler, MD; Jeffrey Newcorn, MD; Mark Stein, PhD Author Information and Disclosures Release Date: March 14, 2008; Valid for credit through March 14, 2009 | Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians | | This CME activity, "Attention Deficit Hyperactivity Disorder and Co-Morbid Conditions in Adolescents and Adults," was developed for presentation on Medscape.
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME Activity Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 University of California, Irvine School of Medicine. |
|
|
Learning Objectives Upon completion of this activity, participants should be able to: Diagnose ADHD by selecting and utilizing the various screening, assessment, and diagnostic tools currently available. Manage adolescent and adult patients with ADHD through an improved understanding of the role of combination
pharmacotherapy; and when and how to switch treatments in adult ADHD. Identify how co-morbid psychiatric or medical conditions associated with ADHD affect treatment choice(s). Authors and Disclosures Lenard Adler, MD
Disclosure: Grant/Research Support: Abbott Laboratories, Bristol-Myers Squibb,
Cortex Pharmaceuticals, Eli Lilly, Merck & Co., National Institute of Mental Health, Neurosearch, Novartis Pharmaceuticals, Ortho-McNeil, Pfizer Inc, Shire Pharmaceuticals, Inc.; Consultant: Abbott Laboratories, Cephalon, Cortex Pharmacuticals, Eli Lilly, Merck & Co., Novartis Pharmaceuticals, Ortho-McNeil, Pfizer Inc, Shire Pharmaceuticals, Inc.; Speakers' Bureau: Shire Pharmaceuticals, Inc.
Jeffrey Newcorn, MD
Disclosure: Grant/Research Support: Eli Lilly, McNeil Pediatrics, Novartis, Shire Laboratories; Advisory Board: Cephalon, Cortex, Eli Lilly, Lupin, McNeil Pediatrics, Novartis, Pfizer Inc, Shire Laboratories; Speakers' Bureau: Eli Lilly, McNeil Pediatrics, Novartis, Shire Laboratories
Mark Stein, PhD
Disclosure: Grant/Research Support: Cephalon, Eli Lilly & Company, McNeil Pediatrics, Novartis;
Speakers' Bureau: McNeil Pediatrics, Novartis, Shire Pharmaceuticals, Inc.
|
 |
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of University of California, Irvine School of Medicine and The Physicians Academy for Clinical and Management Excellence. University of California, Irvine School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
University of California, Irvine School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
